MiMedx Group, Inc (NASDAQ:MDXG) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of MiMedx Group, Inc (NASDAQ:MDXG) have been given an average rating of “Moderate Buy” by the seven ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $8.50.

Several equities analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of MiMedx Group from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Citizens Jmp decreased their price target on shares of MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating on the stock in a research note on Thursday, April 30th. Weiss Ratings downgraded shares of MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, May 18th. Finally, Craig Hallum cut their price target on shares of MiMedx Group from $10.00 to $7.00 and set a “buy” rating for the company in a report on Friday, April 17th.

MiMedx Group Stock Up 3.1%

Shares of NASDAQ MDXG opened at $3.93 on Friday. The company’s 50-day simple moving average is $3.59 and its 200-day simple moving average is $4.71. The company has a quick ratio of 4.81, a current ratio of 5.39 and a debt-to-equity ratio of 0.07. The firm has a market cap of $585.37 million, a price-to-earnings ratio of 19.65 and a beta of 1.48. MiMedx Group has a 52-week low of $3.03 and a 52-week high of $7.99.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings results on Wednesday, April 29th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.02. The firm had revenue of $58.99 million for the quarter, compared to the consensus estimate of $65.80 million. MiMedx Group had a net margin of 7.88% and a return on equity of 21.03%. Equities analysts predict that MiMedx Group will post -0.01 EPS for the current fiscal year.

Institutional Trading of MiMedx Group

A number of hedge funds and other institutional investors have recently made changes to their positions in MDXG. Sunbelt Securities Inc. acquired a new stake in shares of MiMedx Group during the 1st quarter worth approximately $42,000. Kemnay Advisory Services Inc. acquired a new stake in shares of MiMedx Group during the 4th quarter worth approximately $48,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of MiMedx Group during the 1st quarter worth approximately $65,000. Headlands Technologies LLC acquired a new stake in shares of MiMedx Group during the 2nd quarter worth approximately $72,000. Finally, Jain Global LLC acquired a new stake in shares of MiMedx Group during the 4th quarter worth approximately $73,000. Institutional investors and hedge funds own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.